Furthermore, in a 2022 case–control study in Japan by Momozawa et al. [16] involving 63,828 patients with at least one of 14 different cancer types and 37,086 controls, BRCA1 PVs were again associated with increased risk of GC (OR 5.2, 95% CI 2.6–10.5). The gene discussed is BRCA1; the disease is cancer.